Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL4252301 | 0.90 | CYSLTR2 (0.54) | CYSLTR1CYSLTR2MEN1RECQLBLM | |
| SCHEMBL4540937 | 0.85 | CYSLTR1 (0.64) | CYSLTR1CYSLTR2MEN1RECQLBLM | |
| SCHEMBL1593088 | 0.85 | CYSLTR1 (0.64) | CYSLTR1CYSLTR2MEN1RECQLBLM | |
| SCHEMBL1204494 | 0.85 | CYSLTR1 (0.64) | CYSLTR1CYSLTR2MEN1RECQLBLM | |
| SCHEMBL1115929 | 0.85 | CYSLTR1 (0.64) | CYSLTR1CYSLTR2MEN1RECQLBLM | |
| SCHEMBL1768661 | 0.85 | CYSLTR1 (0.64) | CYSLTR1CYSLTR2MEN1RECQLBLM | |
| SCHEMBL2076669 | 0.85 | CYSLTR1 (0.63) | CYSLTR1CYSLTR2MEN1RECQLBLM | |
| SCHEMBL6111299 | 0.85 | CYSLTR1 (0.63) | CYSLTR1CYSLTR2MEN1RECQLBLM | |
| SCHEMBL1592792 | 0.85 | CYSLTR1 (0.63) | CYSLTR1CYSLTR2MEN1RECQLBLM | |
| SCHEMBL6109991 | 0.85 | CYSLTR1 (0.63) | CYSLTR1CYSLTR2MEN1RECQLBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124657-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONTELUKAST | DR. REDDY'S LABORATORIES, INC. | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124657-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONTELUKAST | PRSS3, LTC4S, CYSLTR1 | CYSLTR1 3/4885CYSLTR2 4/4885MEN1 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.